Publication

APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes

Downloadable Content

Persistent URL
Last modified
  • 08/18/2025
Type of Material
Authors
    Joel W Blanchard, Massachusetts Institute of TechnologyLeyla A Akay, Massachusetts Institute of TechnologyJose Davila-Velderrain, Massachusetts Institute of TechnologyDjuna von Maydell, Massachusetts Institute of TechnologyHansruedi Mathys, Massachusetts Institute of TechnologyShawn M Davidson, Princeton UniversityAudrey Effenberger, Massachusetts Institute of TechnologyChin-Yu Chen, Emory UniversityKristal Maner-Smith, Emory UniversityIhab Hajjar, Emory UniversityEric Ortlund, Emory UniversityMichael Bula, Massachusetts Institute of TechnologyEmre Agbas, Massachusetts Institute of TechnologyAyesha Ng, Massachusetts Institute of TechnologyXueqiao Jiang, Massachusetts Institute of TechnologyMartin Kahn, Massachusetts Institute of TechnologyCristina Blanco-Duque, Massachusetts Institute of TechnologyNicolas Lavoie, Massachusetts Institute of TechnologyLiwang Liu, Massachusetts Institute of TechnologyRicardo Reyes, Icahn School of Medicine at Mt. SinaiYuan-Ta Lin, Massachusetts Institute of TechnologyTak Ko, Massachusetts Institute of TechnologyLea R'Bibo, Icahn Sch Med Mt SinaiWilliam T Ralvenius, Massachusetts Institute of TechnologyDavid A Bennett, Rush UniversityHugh P Cam, Massachusetts Institute of TechnologyManolis Kellis, Massachusetts Institute of TechnologyLi-Huei Tsai, Massachusetts Institute of Technology
Language
  • English
Date
  • 2022-11-10
Publisher
  • NATURE PORTFOLIO
Publication Version
Copyright Statement
  • © 2022, The Author(s), under exclusive licence to Springer Nature Limited
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 611
Issue
  • 7935
Start Page
  • 769
End Page
  • +
Supplemental Material (URL)
Abstract
  • APOE4 is the strongest genetic risk factor for Alzheimer’s disease1–3. However, the effects of APOE4 on the human brain are not fully understood, limiting opportunities to develop targeted therapeutics for individuals carrying APOE4 and other risk factors for Alzheimer’s disease4–8. Here, to gain more comprehensive insights into the impact of APOE4 on the human brain, we performed single-cell transcriptomics profiling of post-mortem human brains from APOE4 carriers compared with non-carriers. This revealed that APOE4 is associated with widespread gene expression changes across all cell types of the human brain. Consistent with the biological function of APOE2–6, APOE4 significantly altered signalling pathways associated with cholesterol homeostasis and transport. Confirming these findings with histological and lipidomic analysis of the post-mortem human brain, induced pluripotent stem-cell-derived cells and targeted-replacement mice, we show that cholesterol is aberrantly deposited in oligodendrocytes—myelinating cells that are responsible for insulating and promoting the electrical activity of neurons. We show that altered cholesterol localization in the APOE4 brain coincides with reduced myelination. Pharmacologically facilitating cholesterol transport increases axonal myelination and improves learning and memory in APOE4 mice. We provide a single-cell atlas describing the transcriptional effects of APOE4 on the aging human brain and establish a functional link between APOE4, cholesterol, myelination and memory, offering therapeutic opportunities for Alzheimer’s disease.
Author Notes
Keywords

Tools

Relations

In Collection:

Items